未登录
分享
收藏
分享
收藏HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)
Wang, L.; Qin, S.; Zhou, Y.; Zhang, S.; Sun, X.; Chen, Z.; Cui, J.; Zhao, P.; Gu, K.; Li, Z.; Wang, J.; Chen, X.; Yao, J.; Shen, L.; Zhou, J.; Wang, G.; Bai, Y.; Wang, Q.; Wang, H.
分享
收藏